Interferon-alpha in the treatment of myeloproliferative diseases

Czech version

Authors: Jarmila Kissová ^1,2
Authors‘ workplace: Oddělení klinické hematologie FN Brno, pracoviště Bohunice ¹; LF MU, Brno ²
Published in: Vnitř Lék 2019; 65(11): 699-703
Category:

Overview

Despite significant progress, the treatment options for myeloproliferative neoplasms (MPN) are still limited. Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its widespread use has been limited by higher frequency of short-term adverse reactions compared to conventional treatment and until recently, by its off-label indication in BCR/ABL negative MPNs. With the development of pegylated forms of IFNα with a more favorable toxicity and pharmacokinetic profile have renewed interest in the use of IFNα in the treatment of MPN. Recent studies confirm that IFNα is important drug capable of reducing the tumor population in MPN. Thus, IFNα is currently a more frequently considered drug in the treatment of MPN and has adopted into of some expert recommendations as a first-line drug for younger patients with various subtypes of MPN.

Keywords:

pegylated interferon-α – essential thrombocythemia – interferon α – myeloproliferative neoplasm – polycythemia vera – primary myelofibrosis

Sources

Isaacs A, Lindemann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147(927): 258–267.
Pardanani A, Lasho TL, Finke C et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21(9): 1960–1963. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.leu.2404810>.
Tefferi A, Guglielmelli P, Larson DR et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507–2513; quiz 2615. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2014–05–579136>.
Linkesch W, Gisslinger H, Ludwig H et al. Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses. Acta Med Austriaca 1985; 12(5): 123–127.
Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006; 108(6): 2037–2040. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2006–03–009860>.
Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22(11): 1990–1998. Dostupné z DOI: <http://dx.doi.org/10.1038/leu.2008.280>.
Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117(18): 4706–4715. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2010–08–258772>.
Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 2016; 30(4): 776–781. Dostupné z DOI: <http://dx.doi.org/10.1038/leu.2015.326>.
Larsen TS, Møller MB, de Stricker K et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14(6): 331–334. Dostupné z DOI: <http://dx.doi.org/10.1179/102453309X12473408860587>.
Quintás-Cardama A, Abdel-Wahab O, Manshouri T et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122(6): 893–901. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2012–07–442012>.
Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007; 18(5–6): 459–471. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cytogfr.2007.06.015>.
Guilhot F, Roy L, Saulnier PJ et al. Immunotherapeutic approaches in chronic myelogenous leukemia. Leuk Lymphoma 2008; 49(4): 629–634. Dostupné z DOI: <http://dx.doi.org/10.1080/10428190801927510>.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 2015; 126(15): 1762–1769. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2015–04–637280>.
Verger E, Cassinat B, Chauveau A et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; 126(24): 2585–2591. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2015–07–659060>.
Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8–32. Dostupné z DOI: <http://dx.doi.org/10.1111/j.0105–2896.2004.00204.x
Billiau A Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev 2006; 17(5): 381–409. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cytogfr.2006.07.001
Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol 2019; 41(1): 5–19. Dostupné z DOI: <http://dx.doi.org/10.1007/s00281–018–0700–2>.
Them NC, Bagienski K, Berg T et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol 2015; 90(4): 288–294. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.23928>.
Utke Rank C, Weis Bjerrum O, Larsen TS et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 2016; 57(2): 348–354. Dostupné z DOI: <http://dx.doi.org/10.3109/10428194.2015.1049171>.
Larsen TS, Bjerrum OW, Pallisgaard N et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; 87(10): 847–850. Dostupné z DOI: <http://dx.doi.org/10.1007/s00277–008–0498–4>.
Gowin K, Jain T, Kosiorek H et al. Pegylated interferon alpha-2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res 2017; 54: 73–77. Dostupné z DOI: <http://dx.doi.org/10.1016/j.leukres.2017.01.006>.
Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006; 107(3): 451–458. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.22026>.
Penka M, Schwarz J, Campr V et al. Shrnutí doporučení České pracovní skupiny pro Ph-negativní myeloproliferativní onemocnění (CZEMP) České hematologické společnosti ČLS JEP pro diagnózu a terapii BCR/ABL-negativních myeloproliferací. Vnitr Lek 2012; 58(2): 163–168.
Hatalova A, Schwarz J, Gotic M et al. Recommendations for the diagnosis and treatment of patients with polycythaemia vera. Eur J Haematol 2018; 101(5): 654–664. Dostupné z DOI: <http://dx.doi.org/10.1111/ejh.13156>.
Barbui T, Tefferi A, Vannucchi AM et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European Leukemia Net Leukemia 2018; 32(5): 1057–1069. Dostupné z DOI: <http://dx.doi.org/10.1038/s41375–018–0077–1>.
Quintás-Cardama A, Abdel-Wahab O, Manshouri T et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122(6): 893–901. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2012–07–442012>.
Ianotto JC, Chauveau A, Boyer-Perrard F et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 2018; 103(3): 438–446. Dostupné z DOI: <http://dx.doi.org/10.3324/haematol.2017.181297>.
Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol 2018; 11(9): 697–706. Dostupné z DOI: <http://dx.doi.org/10.1080/17474086.2018.1506325>.
Melillo L, Tieghi A, Candoni A et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol 2009; 84(10): 636–640. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.21504>.
Barbui T, Barosi G, Birgegard G et al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European Leukemia Net. J Clin Oncol 2011; 29(6): 761–770. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2010.31.8436>.